Skip to Content

Join the 'HIV Infection' group to help and get support from people like you.

HIV Infection News

Related terms: Acquired Immune Deficiency Syndrome, Acquired Immunodeficiency Syndrome (AIDS), Acute HIV Infection, Acute Retroviral Syndrome, AIDS, AIDS-Related Complex, Chronic Symptomatic HIV Infection, HIV Infection, Acute, HIV Seroconversion Syndrome, Human Immunodeficiency Virus Infection, Primary HIV Infection, HIV, ARC, Acquired Immunodeficiency Syndrome, HIV/AIDS

Antibody Shot Protects Monkeys From HIV-Like Infection

Posted 3 days ago by Drugs.com

WEDNESDAY, April 27, 2016 – A single injection of a powerful HIV-fighting antibody protected monkeys from an HIV-like infection for up to six months, scientists report. Researchers from the U.S. National Institute of Allergy and Infectious Diseases (NIAID) found that each of four HIV antibodies helped protect macaque monkeys from repeated exposure to a modified version of HIV, although some of the antibodies protected the animals longer than others. Experts said the findings, published April 28 in the journal Nature, represent progress in a new approach to eventually creating an HIV vaccine. Scientists have worked for decades toward the goal of having an HIV vaccine, with little success. In 2009, a clinical study known as the "Thai trial" produced the first vaccine to offer some protection against HIV, the virus that causes AIDS, but it only lessened transmission by a modest degree. ... Read more

Related support groups: HIV Infection, Pre-Exposure Prophylaxis, Diagnosis and Investigation, Vaccination and Prophlaxis

People With HIV May Age Faster, Study Suggests

Posted 9 days ago by Drugs.com

THURSDAY, April 21, 2016 – People with HIV may age prematurely, putting them at increased risk for an earlier death, a new study indicates. With antiretroviral therapy, many people with HIV can expect to live for decades after being infected with the AIDS-causing virus. However, doctors have noted that these patients often show signs of premature aging. Using what they called a highly accurate marker for aging on a biological level, the study authors reported that HIV seems to cause an average of nearly five years of premature aging. This increases the risk of early death by 19 percent, according to the study published April 21 in the journal Molecular Cell. "The medical issues in treating people with HIV have changed," said study co-author Howard Fox, a professor in the department of pharmacology and experimental neuroscience at the University of Nebraska Medical Center in Omaha. ... Read more

Related support groups: HIV Infection, Pre-Exposure Prophylaxis, Incivek, Baraclude, Victrelis, Kaletra, Viread, Tenofovir, Norvir, Entecavir, Telaprevir, Nevirapine, Boceprevir, Lamivudine, Reyataz, Prezista, Abacavir, Lexiva, Norvir Soft Gelatin, Hepsera

HIV Patients Now Living Long Enough to Develop Alzheimer's

Posted 11 days ago by Drugs.com

TUESDAY, April 19, 2016 – The first case of Alzheimer's disease diagnosed in a person with HIV highlights the fact that long-time HIV survivors are starting to reach ages where their risk for Alzheimer's increases, researchers report. The 71-year-old man was diagnosed after a medical scan revealed amyloid protein clumps in his brain. Until now, it was believed that HIV-related inflammation in the brain might prevent the formation of such clumps and thereby protect these people from Alzheimer's. "This patient may be a sentinel case that disputes what we thought we knew about dementia in HIV-positive individuals," said study author Dr. R. Scott Turner. He is head of the Memory Disorders Program at Georgetown University Medical Center in Washington, D.C. The case also suggests that some older people with HIV and dementia may be misdiagnosed with HIV-associated brain disorders, but ... Read more

Related support groups: HIV Infection, Dementia, Alzheimer's Disease, Pre-Exposure Prophylaxis, Mild Cognitive Impairment, Arteriosclerotic Dementia, Arteriosclerotic Dementia w/ Depressive Features, Lewy Body Dementia

FDA Approves Descovy (emtricitabine and tenofovir alafenamide), Gilead’s Third TAF-Based HIV Therapy

Posted 5 Apr 2016 by Drugs.com

FOSTER CITY, Calif., April 04, 2016 --(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Descovy® (emtricitabine 200 mg/tenofovir alafenamide 25 mg, F/TAF), a fixed-dose combination for the treatment of HIV. Descovy is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older. Descovy is not indicated for use as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults at high risk. Descovy has a boxed warning in its product label regarding the risks of lactic acidosis/severe hepatomegaly with steatosis, and post treatment acute exacerbation of hepatitis B. See below for important safety information. TAF is a novel targeted prodrug of tenofovir that has demonstrated high antiviral ... Read more

Related support groups: HIV Infection, Truvada, Tenofovir, Emtricitabine, Descovy, Emtricitabine/Tenofovir, Emtricitabine/tenofovir Alafenamide

Doctors Report Groundbreaking HIV-to-HIV Organ Transplants

Posted 31 Mar 2016 by Drugs.com

WEDNESDAY, March 30, 2016 – Trailblazing liver and kidney transplants from an HIV-positive donor to HIV-positive recipients were announced Wednesday by surgeons at Johns Hopkins University. "A couple of weeks ago, we performed the first HIV-to-HIV liver transplant in the world and the first HIV-to-HIV kidney transplant in the United States," Dr. Dorry Segev said during a midday media briefing. Before 2013 and passage of the HIV Organ Policy Equity Act, this kind of medical advance would not have been possible, because it was illegal for HIV-positive patients to donate organs in the United States. The act allows HIV-positive donors to donate organs to patients infected with the AIDS-causing virus, Segev said. Until the law was changed, thousands of patients with HIV in need of organ transplants often risked death while waiting for a donated organ, he said. At the same time, "we were ... Read more

Related support groups: HIV Infection, Pre-Exposure Prophylaxis, Organ Transplant - Rejection Prophylaxis, Organ Transplant, Graft-versus-host disease, Rejection Prophylaxis

Work With Monkeys May Benefit HIV Babies

Posted 22 Mar 2016 by Drugs.com

TUESDAY, March 22, 2016 – Treating baby monkeys within 24 hours of exposure to an HIV-like virus eliminated the virus, a new study says. The findings suggest that giving antibodies to human infants infected with HIV by their mothers might clear the AIDS-causing virus from their bodies, according to the researchers. "We knew going into this study that HIV infection spreads very quickly in infants during mother-to-child transmission," said study senior author Nancy Haigwood, director of the Oregon National Primate Research Center at Oregon Health & Science University. "So we knew that we had to treat the infant rhesus macaques quickly but we were not convinced an antibody treatment could completely clear the virus after exposure. We were proven wrong," she said in a university news release. The study was published March 21 in the journal Nature Medicine. Rates of mother-to-child HIV ... Read more

Related support groups: HIV Infection, Pre-Exposure Prophylaxis, Diagnosis and Investigation

FDA Approves Odefsey (emtricitabine, rilpivirine and tenofovir alafenamide) for the Treatment of HIV-1 Infection

Posted 8 Mar 2016 by Drugs.com

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mar. 1, 2016-- Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Odefsey (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg or R/F/TAF) for the treatment of HIV-1 infection in certain patients. Emtricitabine and tenofovir alafenamide are from Gilead Sciences and rilpivirine is from Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen). Odefsey is Gilead’s second TAF-based regimen to receive FDA approval and represents the smallest pill of any single tablet regimen for the treatment of HIV. Odefsey is indicated as a complete regimen for the treatment of HIV-1 infection in patients 12 years of age and older who have no antiretroviral treatment history and HIV-1 RNA levels less than or equal to 100,000 copies per mL. O ... Read more

Related support groups: HIV Infection, Complera, Odefsey, Emtricitabine/rilpivirine/tenofovir, Emtricitabine/rilpivirine/tenofovir Alafenamide

In Monkeys, Therapy Flushes HIV-Like Virus From Its Hiding Places

Posted 26 Feb 2016 by Drugs.com

FRIDAY, Feb. 26, 2016 – One of the key roadblocks to a cure for HIV infection and AIDS is the fact that the virus can "hide out" in a dormant state in immune system cells, evading treatment. However, research in monkeys suggests that a new approach might push these hidden cells out of hiding, to where they can be destroyed by conventional antiretroviral drug therapy [ART]. The finding would need to be replicated in people, and many animal studies don't pan out in humans. Still, the research team from Emory University in Atlanta believes the therapy might some day "effectively diminish [the] HIV reservoir under ART as a means to establish a functional cure." The findings were presented Thursday at the annual Conference on Retroviruses and Opportunistic Infections in Boston. Experts note that research presented at medical meetings is typically considered preliminary until published in a ... Read more

Related support groups: HIV Infection

Half of Gay Black Men May Become Infected With HIV, CDC Says

Posted 23 Feb 2016 by Drugs.com

TUESDAY, Feb. 23, 2016 – If current HIV rates continue, about half of gay and bisexual black men in the United States will be diagnosed with the AIDS-causing virus in their lifetime, a new government analysis says. Gay and bisexual Hispanic males – another population group at serious risk of HIV – have a one in four chance of contracting HIV, according to the report from the U.S. Centers for Disease Control and Prevention. "As alarming as these lifetime risk estimates are, they are not a foregone conclusion. They are a call to action," said Dr. Jonathan Mermin, director of the CDC's National Center for HIV/AIDS, Viral Hepatitis, STD, and Tuberculosis Prevention. "The prevention and care strategies we have at our disposal today provide a promising outlook for future reductions of HIV infections and disparities in the U.S., but hundreds of thousands of people will be diagnosed in their ... Read more

Related support groups: Opiate Dependence, Drug Dependence, HIV Infection, Pre-Exposure Prophylaxis, Toxic Reactions Incl Drug and Substance Abuse

Prenatal Use of HIV Drug May Slow Child's Development Slightly

Posted 23 Feb 2016 by Drugs.com

TUESDAY, Feb. 23, 2016 – A drug used to prevent mother-to-child HIV transmission during pregnancy may slow language development slightly in children, a new study suggests. Researchers followed more than 900 infants who were born to HIV-positive mothers but were not infected by the AIDS-causing virus. All of the mothers took antiretroviral drugs during pregnancy. Some of the treatment regimens included a drug called atazanavir (Reyataz), while others did not. The infants underwent a standard test of development at 1 year of age. The 167 infants whose mothers took atazanavir during pregnancy had slightly lower language and social development scores than the 750 infants whose mothers did not take the drug. But the study only showed an association between atazanavir and language delays in children, and did not prove a cause-and-effect link. And the difference in social development scores ... Read more

Related support groups: Harvoni, HIV Infection, Atripla, Pre-Exposure Prophylaxis, Incivek, Truvada, Stribild, Triumeq, Complera, Victrelis, Baraclude, Kaletra, Viread, Tenofovir, Norvir, Telaprevir, Entecavir, Viekira Pak, Lamivudine, Boceprevir

Vaginal Ring Offers Some Protection Against HIV, Study Says

Posted 23 Feb 2016 by Drugs.com

MONDAY, Feb. 22, 2016 – An insertable vaginal ring containing a month's supply of a continuous-release HIV prevention drug reduced the risk of HIV in African women by at least 27 percent, a new study found. The ring works by slowly and continuously delivering a highly localized and controlled amount of the antiretroviral medication dapivirine. This drug aims to halt the ability of HIV – the virus that causes AIDS – to replicate inside a healthy cell. The goal: to prevent HIV infection, rather than treat it, the researchers said. "These results come after a number of challenging years in the effort to find ways to improve HIV control," said study lead author Dr. Jared Baeten, a professor in the departments of global health, medicine and epidemiology at the University of Washington in Seattle. "But while the dapivirine vaginal ring isn't commercially available yet, I'm really very ... Read more

Related support groups: Harvoni, HIV Infection, Atripla, Pre-Exposure Prophylaxis, Incivek, Truvada, Stribild, Triumeq, Complera, Viral Infection, Victrelis, Baraclude, Kaletra, Tenofovir, Viread, Norvir, Viekira Pak, Telaprevir, Entecavir, Boceprevir

Alcohol More Harmful for People With HIV, Study Suggests

Posted 9 Feb 2016 by Drugs.com

MONDAY, Feb. 8, 2016 – Drinking alcohol may be more dangerous for people infected with HIV, a new study suggests. The effects of alcohol appear to be more pronounced for those with the virus that causes AIDS, even when the virus is suppressed with modern antiretroviral treatment (ART), the Yale University researchers reported. They noted that HIV patients who have just one or two drinks a day are at greater risk for death or alcohol-related health issues. The study involved patients treated by the U.S. Department of Veterans Affairs between 2008 and 2012. There were more than 18,000 HIV-positive patients and over 42,000 people not infected with the virus. The researchers investigated the link between drinking alcohol, death and other health issues the patients developed. They found the patients with HIV who drank even moderate amounts of alcohol were more likely to develop ... Read more

Related support groups: HIV Infection, Alcohol Dependence, Tamiflu, Pre-Exposure Prophylaxis, Incivek, Alcoholism, Hangover, Baraclude, Victrelis, Kaletra, Viread, Oseltamivir, Tenofovir, Norvir, Telaprevir, Entecavir, Boceprevir, Nevirapine, Lamivudine, Reyataz

CDC: Black Americans With HIV Still Less Likely to Get Ongoing Medical Care

Posted 5 Feb 2016 by Drugs.com

FRIDAY, Feb. 5, 2016 – While HIV diagnoses dropped significantly over the past decade in the United States, blacks with HIV are less likely than whites or Hispanics to receive routine, ongoing care, according to the U.S. Centers for Disease Control and Prevention. From 2005 to 2014, annual HIV diagnoses fell 19 percent in the United States. Infections among black women dropped 42 percent during this period. Despite this progress in the fight against HIV, racial disparities persist, the CDC found. While black people make up 12 percent of the U.S. population, they accounted for nearly half of all HIV diagnoses in 2014. "CDC has been working for many years to eliminate the HIV disparities that exist within the black community," Dr. Eugene McCray, director of the CDC's Division of HIV/AIDS Prevention, said in an agency news release. "While we are seeing signs of success, we must continue ... Read more

Related support groups: Harvoni, HIV Infection, Tamiflu, Atripla, Pre-Exposure Prophylaxis, Incivek, Truvada, Stribild, Triumeq, Complera, Victrelis, Baraclude, Kaletra, Oseltamivir, Viread, Tenofovir, Norvir, Telaprevir, Viekira Pak, Entecavir

Scientists Piggyback Experimental HIV Vaccine on Cold Viruses

Posted 2 Feb 2016 by Drugs.com

TUESDAY, Feb. 2, 2016 – Scientists report progress in their bid to develop ways to piggyback an HIV vaccine on germs that cause colds. In the new study, Harvard researchers said they successfully used cold viruses to deliver an experimental HIV vaccine to humans. The approach "appears to be safe and well-tolerated, and the injection induces a moderate immune response against HIV in humans," said Dr. James Crowe, director of Vanderbilt Vaccine Center in Nashville. He was not involved in the study. The research doesn't mean that a long-sought HIV vaccine is near; these scientists focused on developing better ways to deliver a potential vaccine into the immune system. Researchers have long sought to develop a vaccine against HIV, but the virus is especially stubborn. "Most experimental vaccines tested to date don't seem to induce strong or protective immune responses," Crowe said. Even ... Read more

Related support groups: HIV Infection, Cold Symptoms, Pre-Exposure Prophylaxis, Vaccination and Prophlaxis

Resistance to HIV Drug Growing, Study Finds

Posted 29 Jan 2016 by Drugs.com

FRIDAY, Jan. 29, 2016 – HIV resistance to the antiretroviral drug tenofovir (Viread) is increasingly common, a new study finds. The researchers said their finding is surprising and alarming because the drug plays a major role in treating and preventing infection with HIV, the virus that causes AIDS. "Tenofovir is a critical part of our armamentarium against HIV, so it is extremely concerning to see such a high level of resistance to this drug," study author Dr. Ravi Gupta, from the department of infection and immunity at University College London in England, said in a university news release. "It is very potent drug with few side effects, and there aren't any good alternatives that can be deployed using a public health approach. Tenofovir is used not only to treat HIV but also to prevent it in high-risk groups, so we urgently need to do more to combat the problem of emerging ... Read more

Related support groups: HIV Infection, Atripla, Pre-Exposure Prophylaxis, Truvada, Stribild, Complera, Viral Infection, Viread, Tenofovir, Genvoya, Emtricitabine/lopinavir/ritonavir/tenofovir, Emtricitabine/rilpivirine/tenofovir, Cobicistat/elvitegravir/emtricitabine/tenofovir, Efavirenz/Emtricitabine/Tenofovir, Emtricitabine/nelfinavir/tenofovir, Emtricitabine/Tenofovir

Page 1 2 3 ... Next

Ask a Question

Further Information

Related Condition Support Groups

Pre-Exposure Prophylaxis, Viral Infection

Related Drug Support Groups

Atripla, Truvada, Stribild, Triumeq, Complera, Kaletra, Viread, tenofovir, Norvir, view more... Reyataz, Genvoya, lamivudine, nevirapine, ritonavir, Privigen, Norvir Soft Gelatin, abacavir, Prezista, Epivir, Combivir, Lexiva, Epzicom, Intelence, Sandoglobulin, Trizivir, Sustiva, dolutegravir, indinavir, Tivicay, didanosine, Prezcobix, immune globulin intravenous, efavirenz, Carimune, Fuzeon, Ziagen, Edurant, Agenerase, Telzir, lamivudine / zidovudine, darunavir, Retrovir, Odefsey, raltegravir, zidovudine, stavudine, amprenavir, abacavir / dolutegravir / lamivudine, Isentress, atazanavir, nelfinavir, Venoglobulin-S 10%, Dutrebis, Selzentry, Descovy, Evotaz, Gammagard S / D, Venoglobulin-S 5%, Panglobulin, Panglobulin NF, Carimune NF, Gamimune, Gammaplex, Viramune XR, Gammar IV, Zerit XR, Octagam, Vitekta, Tybost, Polygam S / D, Gamimune N 5%, Iveegam En, Gamimune N 10%, Gammar-P IV, Crixivan, etravirine, zalcitabine, tipranavir, saquinavir, emtricitabine / lopinavir / ritonavir / tenofovir, emtricitabine / nelfinavir / tenofovir, cobicistat / elvitegravir / emtricitabine / tenofovir, emtricitabine / rilpivirine / tenofovir, rilpivirine, maraviroc, lopinavir / ritonavir, delavirdine, abacavir / lamivudine / zidovudine, abacavir / lamivudine, efavirenz / emtricitabine / tenofovir, emtricitabine, fosamprenavir, enfuvirtide, emtricitabine / tenofovir, elvitegravir, cobicistat, Viramune, Viracept, Epivir-HBV, Fortovase, Invirase, Hivid, Aptivus, Zerit, Emtriva, Videx EC, lamivudine / raltegravir, cobicistat / darunavir, atazanavir / cobicistat, cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide, emtricitabine / rilpivirine / tenofovir alafenamide, Videx, Rescriptor, emtricitabine / tenofovir alafenamide, Flebogamma